Author: Matthew Nelson|| Date Published: May 20, 2020
Richmond, Va.-based pharmaceutical manufacturing company Phlow will lead a team comprised of Civica Rx, Ampac Fine Chemicals and the Virginia Commonwealth University’s Medicines for All Institute to produce critical medicines for COVID-19 response through a potential 10-year, $812M contract from the Biomedical Advanced Research and Development Authority.
The team will develop chemical compounds for active pharmaceutical ingredients in an effort to help the government avoid or address drug shortages amid the coronavirus pandemic, the Department of Health and Human Services said Tuesday.
According to HHS, the alliance will apply advanced manufacturing systems and transfer a novel continuous production technology to designated businesses or other entities.
The Phlow-led group will initially receive $354M over four years as part of the agreement with BARDA and may extend work under the contract to provide system and supplies maintenance support.
“Utilizing advanced manufacturing processes increases the speed we can provide patients with treatments, reduces the likelihood of drug shortages and increases U.S. readiness," said Gary Disbrow, acting director of BARDA.
GreyNoise Intelligence has launched a command-and-control detection capability designed to give federal agencies earlier visibility into compromised infrastructure. GreyNoise’s new…
Textron Aviation Defense has been awarded a five-year, $150 million contract to provide sustaining engineering and program management, or SEPM, services…
Merlin, an aerospace and defense technology company, has appointed former PsiQuantum executive Mark Brunner as chief revenue officer. What Will Mark Brunner Oversee?…
Fortreum has acquired Kovr.AI, an AI-native cybersecurity compliance platform, to combine automated compliance capabilities with independent assessment services for federal…
